Question · asked by 1 review
Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone: Quality of life: CFQ‐R respiratory domain: absolute change from baseline
- Population
- adults and children with cystic fibrosis
- Intervention
- Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor
- Comparison
- placebo or ivacaftor alone
- Outcome
- Quality of life: CFQ‐R respiratory domain: absolute change from baseline
What each review found
Current versions onlyNo studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 2 · 66.7%High 0 · 0%
| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane Headline outcomes only | no estimate extracted | 5 studies · 946 participants | Low |
Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2020) · Cochrane Headline outcomes onlyearlier version CD010966.PUB3, superseded | no estimate extracted | 2 studies · 522 participants | Moderate |
Summary of findings ‐ tezacaftor plus ivacaftor vs placebo or ivacaftor alone Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2018) · Cochrane Headline outcomes onlyearlier version CD010966.PUB2, superseded | no estimate extracted | 2 studies · 522 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del) 2023 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.